American Society of Hematology, Blood, 17(130), p. 1889-1897
DOI: 10.1182/blood-2017-05-785790
Full text: Unavailable
Key Points After hydroxycarbamide therapy in high-risk ET, ruxolitinib showed no improvement for complete or partial response rates compared with BAT. Ruxolitinib significantly improved some disease-related symptoms, but rates of thrombosis, hemorrhage, or transformation were not different.